Zephyr^® Valves: Most Studied. Most Proven. Most Used Valves for Severe COPD/Emphysema.*

The Zephyr Valve is a clinically-proven bronchoscopic treatment for patients with severe COPD/emphysema who suffer from dypsnea despite optimised medical therapy.

The 2024 GOLD Report summarised the following patient benefits reported in clinical studies on Endobronchial Valve (EBV) Treatment for severe COPD/emphysema:⁴²

Improved FEV₁, 6MWD, and health status at 6 and 12 months**
Improved survival after successful treatment (4 retrospective studies)
Decreased exacerbations
Decreased respiratory failure episodes

Complications of the Zephyr Valve treatment can include, but are not limited to, pneumothorax, worsening of COPD symptoms, hemoptysis, pneumonia, dyspnea and, in rare cases, death.

*Data on file at Pulmonx
**Quality and quantity of data was rated “Evidence Level A.”

Consistent Clinical Findings
Across Four Randomised Controlled Trials

RCT	Design	Sample size & follow-up period	Procedural Success (TLVR%)	Difference Zephyr Valve vs. Control Groups (ITT)
RCT	Design	Sample size & follow-up period	Procedural Success (TLVR%)	Lung function (fev₁%) MCID = 10%-15%	Excercise capacity (6mwd) MCID = 26 m	quality of life (sgrq) MCID = -4 pts
LIBERATE¹	2:1 Randomisation Heterogeneous only Multicentre	n=190 12 months	84%	18.0% p<0.001	39 m p=0.002	-7.1 pts p=0.004
TRANSFORM²	2:1 Randomisation Heterogeneous only Multicentre	n=97 6 months	90%	29.3% p<0.001	79 m p<0.001	-6.5 pts p=0.031
IMPACT³	1:1 Randomisation Homogeneous only Multicentre	n=93 6 months*	89%	16.3% p<0.001	28 m p=0.016	-7.5 pts p<0.001
STELVIO^4,5	1:1 Randomisation Heterogeneous & Homogeneous Single Centre	n=68 6 months	88%	17.8% p=0.001	74 m p<0.001	-14.7 pts** p<0.001

Completed cases, all other values listed are ITT population

*Data on file at Pulmonx (not in publication)

**Completed cases, all other values listed are ITT population

Recent Clinical Data

2023 GOLD Report Summary

The 2023 GOLD Report highlights patient benefits resulting from Endobronchial Valve treatment.

Study on Improved Survival

A single-centre, retrospective study that found improved survival of 1.7 years after Zephyr Valve treatment.

Study on Exacerbations

A single-centre retrospective study examines the number of exacerbations before and after endobronchial/endoscopic lung volume reduction.

Download Summary

2023 GOLD Report Summary

The 2023 GOLD Report highlights patient benefits resulting from Endobronchial Valve treatment.

Download Summary

Study on Improved Survival

A single-centre, retrospective study that found improved survival of 1.7 years after Zephyr Valve treatment.

Download Summary

Study on Exacerbations

A single-centre retrospective study examines the number of exacerbations before and after endobronchial/endoscopic lung volume reduction.

Download Summary

Download Clinical Study Summaries

Click the logo to download the summary

Patient Treatment Preference

Patients with severe emphysema perceive that a procedure with risks and benefits of the Zephyr Valve is desirable over continued medical management or LVRS.

In a study conducted before Zephyr Valves were widely available or well-known, researchers identified a strong preference for a treatment with its clinical benefits and risks.⁸

76% of respondents said they would select a treatment option similar to Zephyr Valves when compared with their current treatment.
294 severe emphysema patients were surveyed.

Hear from Patients Treated with Zephyr Valves

Patient Treatment Preference

Patients with severe emphysema perceive that a procedure with risks and benefits of the Zephyr Valve is desirable over continued medical management or LVRS.

In a study conducted before Zephyr Valves were widely available or well-known, researchers identified a strong preference for a treatment with its clinical benefits and risks.⁸

76% of respondents said they would select a treatment option similar to Zephyr Valves when compared with their current treatment.
294 severe emphysema patients were surveyed.

Hear from Patients Treated with Zephyr Valves

International Guidance Documents Include Endobronchial Valve Treatment as an Option for Emphysema Patients

Multiple independent networks have concluded that with proper patient selection, endobronchial valves, such as Zephyr Valves, should be considered in the treatment of severe emphysema.

The quality of evidence for treatment with endobronchial valves has been graded “A” by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).¹⁰

The United Kingdom’s National Institute for Health and Care Excellence (NICE) has included this treatment as part of standard measures for COPD and recommended all qualifying patients be evaluated for eligibility.^11,34